The role of E3 ubiquitin ligases in the development and progression of glioblastoma.
Journal
Cell death and differentiation
ISSN: 1476-5403
Titre abrégé: Cell Death Differ
Pays: England
ID NLM: 9437445
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
16
07
2020
accepted:
20
11
2020
revised:
17
11
2020
pubmed:
13
1
2021
medline:
16
12
2021
entrez:
12
1
2021
Statut:
ppublish
Résumé
Despite recent advances in our understanding of the disease, glioblastoma (GB) continues to have limited treatment options and carries a dismal prognosis for patients. Efforts to stratify this heterogeneous malignancy using molecular classifiers identified frequent alterations in targetable proteins belonging to several pathways including the receptor tyrosine kinase (RTK) and mitogen-activated protein kinase (MAPK) signalling pathways. However, these findings have failed to improve clinical outcomes for patients. In almost all cases, GB becomes refractory to standard-of-care therapy, and recent evidence suggests that disease recurrence may be associated with a subpopulation of cells known as glioma stem cells (GSCs). Therefore, there remains a significant unmet need for novel therapeutic strategies. E3 ubiquitin ligases are a family of >700 proteins that conjugate ubiquitin to target proteins, resulting in an array of cellular responses, including DNA repair, pro-survival signalling and protein degradation. Ubiquitin modifications on target proteins are diverse, ranging from mono-ubiquitination through to the formation of polyubiquitin chains and mixed chains. The specificity in substrate tagging and chain elongation is dictated by E3 ubiquitin ligases, which have essential regulatory roles in multiple aspects of brain cancer pathogenesis. In this review, we begin by briefly summarising the histological and molecular classification of GB. We comprehensively describe the roles of E3 ubiquitin ligases in RTK and MAPK, as well as other, commonly altered, oncogenic and tumour suppressive signalling pathways in GB. We also describe the role of E3 ligases in maintaining glioma stem cell populations and their function in promoting resistance to ionizing radiation (IR) and chemotherapy. Finally, we consider how our knowledge of E3 ligase biology may be used for future therapeutic interventions in GB, including the use of blood-brain barrier permeable proteolysis targeting chimeras (PROTACs).
Identifiants
pubmed: 33432111
doi: 10.1038/s41418-020-00696-6
pii: 10.1038/s41418-020-00696-6
pmc: PMC7862665
doi:
Substances chimiques
Antineoplastic Agents
0
Polyubiquitin
120904-94-1
Ubiquitin-Protein Ligases
EC 2.3.2.27
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
522-537Subventions
Organisme : Medical Research Council
ID : MC_UU_00001/7
Pays : United Kingdom
Références
Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807–12.
pubmed: 18772396
pmcid: 2820389
doi: 10.1126/science.1164382
Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174:1149–53.
pubmed: 19246647
pmcid: 2671348
doi: 10.2353/ajpath.2009.080958
Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013;19:764–72.
pubmed: 23209033
doi: 10.1158/1078-0432.CCR-12-3002
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.
pubmed: 15758009
doi: 10.1056/NEJMoa043330
Lee SY. Temozolomide resistance in glioblastoma multiforme. Genes Dis. 2016;3:198–210.
pubmed: 30258889
pmcid: 6150109
doi: 10.1016/j.gendis.2016.04.007
Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer. 2004;4:296–307.
pubmed: 15057289
doi: 10.1038/nrc1319
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003.
pubmed: 15758010
doi: 10.1056/NEJMoa043331
Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, et al. The epidemiology of glioma in adults: a “state of the science” review. Neuro Oncol. 2014;16:896–913.
pubmed: 24842956
pmcid: 4057143
doi: 10.1093/neuonc/nou087
Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155:462–77.
pubmed: 24120142
pmcid: 3910500
doi: 10.1016/j.cell.2013.09.034
Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, Langdon WY, et al. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev. 1998;12:3663–74.
pubmed: 9851973
pmcid: 317257
doi: 10.1101/gad.12.23.3663
Lill NL, Douillard P, Awwad RA, Ota S, Lupher ML Jr., Miyake S, et al. The evolutionarily conserved N-terminal region of Cbl is sufficient to enhance down-regulation of the epidermal growth factor receptor. J Biol Chem. 2000;275:367–77.
pubmed: 10617627
doi: 10.1074/jbc.275.1.367
Lee PS, Wang Y, Dominguez MG, Yeung YG, Murphy MA, Bowtell DD, et al. The Cbl protooncoprotein stimulates CSF-1 receptor multiubiquitination and endocytosis, and attenuates macrophage proliferation. EMBO J. 1999;18:3616–28.
pubmed: 10393178
pmcid: 1171440
doi: 10.1093/emboj/18.13.3616
Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I, et al. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell. 1999;4:1029–40.
pubmed: 10635327
doi: 10.1016/S1097-2765(00)80231-2
de Melker AA, van der Horst G, Calafat J, Jansen H, Borst J. c-Cbl ubiquitinates the EGF receptor at the plasma membrane and remains receptor associated throughout the endocytic route. J Cell Sci. 2001;114:2167–78.
pubmed: 11493652
Huang F, Kirkpatrick D, Jiang X, Gygi S, Sorkin A. Differential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domain. Mol Cell. 2006;21:737–48.
pubmed: 16543144
doi: 10.1016/j.molcel.2006.02.018
Sugawa N, Ekstrand AJ, James CD, Collins VP. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA. 1990;87:8602–6.
pubmed: 2236070
doi: 10.1073/pnas.87.21.8602
pmcid: 55005
Han W, Zhang T, Yu H, Foulke JG, Tang CK. Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII. Cancer Biol Ther. 2006;5:1361–8.
pubmed: 16969069
doi: 10.4161/cbt.5.10.3226
Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA. 1994;91:7727–31.
pubmed: 8052651
doi: 10.1073/pnas.91.16.7727
pmcid: 44475
Davies GC, Ryan PE, Rahman L, Zajac-Kaye M, Lipkowitz S. EGFRvIII undergoes activation-dependent downregulation mediated by the Cbl proteins. Oncogene. 2006;25:6497–509.
pubmed: 16702950
pmcid: 2274962
doi: 10.1038/sj.onc.1209662
Grandal MV, Zandi R, Pedersen MW, Willumsen BM, van Deurs B, Poulsen HS. EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes. Carcinogenesis. 2007;28:1408–17.
pubmed: 17372273
doi: 10.1093/carcin/bgm058
Li JJ, Liu DP, Liu GT, Xie D. EphrinA5 acts as a tumor suppressor in glioma by negative regulation of epidermal growth factor receptor. Oncogene. 2009;28:1759–68.
pubmed: 19270726
doi: 10.1038/onc.2009.15
Li Z, Dong T, Proschel C, Noble M. Chemically diverse toxicants converge on Fyn and c-Cbl to disrupt precursor cell function. PLoS Biol. 2007;5:e35.
pubmed: 17298174
pmcid: 1790953
doi: 10.1371/journal.pbio.0050035
Stevens BM, Folts CJ, Cui W, Bardin AL, Walter K, Carson-Walter E, et al. Cool-1-mediated inhibition of c-Cbl modulates multiple critical properties of glioblastomas, including the ability to generate tumors in vivo. Stem Cells. 2014;32:1124–35.
pubmed: 24458840
doi: 10.1002/stem.1644
Chen HY, Yang YM, Stevens BM, Noble M. Inhibition of redox/Fyn/c-Cbl pathway function by Cdc42 controls tumour initiation capacity and tamoxifen sensitivity in basal-like breast cancer cells. EMBO Mol Med. 2013;5:723–36.
pubmed: 23606532
pmcid: 3662315
doi: 10.1002/emmm.201202140
Wu WJ, Tu S, Cerione RA. Activated Cdc42 sequesters c-Cbl and prevents EGF receptor degradation. Cell. 2003;114:715–25.
pubmed: 14505571
doi: 10.1016/S0092-8674(03)00688-3
Zhang J, Antonyak MA, Singh G, Cerione RA. A mechanism for the upregulation of EGF receptor levels in glioblastomas. Cell Rep. 2013;3:2008–20.
pubmed: 23770238
pmcid: 3742030
doi: 10.1016/j.celrep.2013.05.021
Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I, et al. Somatic mutations of the Parkinson’s disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet. 2010;42:77–82.
pubmed: 19946270
doi: 10.1038/ng.491
Lin DC, Xu L, Chen Y, Yan H, Hazawa M, Doan N, et al. Genomic and functional analysis of the E3 ligase PARK2 in glioma. Cancer Res. 2015;75:1815–27.
pubmed: 25877876
pmcid: 4417379
doi: 10.1158/0008-5472.CAN-14-1433
Di K, Linskey ME, Bota DA. TRIM11 is overexpressed in high-grade gliomas and promotes proliferation, invasion, migration and glial tumor growth. Oncogene. 2013;32:5038–47.
pubmed: 23178488
doi: 10.1038/onc.2012.531
Wei N, Serino G, Deng XW. The COP9 signalosome: more than a protease. Trends Biochem Sci. 2008;33:592–600.
pubmed: 18926707
doi: 10.1016/j.tibs.2008.09.004
Hou J, Deng Q, Zhou J, Zou J, Zhang Y, Tan P, et al. CSN6 controls the proliferation and metastasis of glioblastoma by CHIP-mediated degradation of EGFR. Oncogene. 2017;36:1134–44.
pubmed: 27546621
doi: 10.1038/onc.2016.280
Wang T, Yang J, Xu J, Li J, Cao Z, Zhou L, et al. CHIP is a novel tumor suppressor in pancreatic cancer through targeting EGFR. Oncotarget. 2014;5:1969–86.
pubmed: 24722501
pmcid: 4039121
doi: 10.18632/oncotarget.1890
Gao T, Furnari F, Newton AC. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell. 2005;18:13–24.
pubmed: 15808505
doi: 10.1016/j.molcel.2005.03.008
Winston JT, Strack P, Beer-Romero P, Chu CY, Elledge SJ, Harper JW. The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev. 1999;13:270–83.
pubmed: 9990852
pmcid: 316433
doi: 10.1101/gad.13.3.270
Li X, Liu J, Gao T. beta-TrCP-mediated ubiquitination and degradation of PHLPP1 are negatively regulated by Akt. Mol Cell Biol. 2009;29:6192–205.
pubmed: 19797085
pmcid: 2786696
doi: 10.1128/MCB.00681-09
Laney JD, Hochstrasser M. Substrate targeting in the ubiquitin system. Cell. 1999;97:427–30.
pubmed: 10338206
doi: 10.1016/S0092-8674(00)80752-7
Warfel NA, Niederst M, Stevens MW, Brennan PM, Frame MC, Newton AC. Mislocalization of the E3 ligase, beta-transducin repeat-containing protein 1 (beta-TrCP1), in glioblastoma uncouples negative feedback between the pleckstrin homology domain leucine-rich repeat protein phosphatase 1 (PHLPP1) and Akt. J Biol Chem. 2011;286:19777–88.
pubmed: 21454620
pmcid: 3103356
doi: 10.1074/jbc.M111.237081
Chan CH, Li CF, Yang WL, Gao Y, Lee SW, Feng Z, et al. The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell. 2012;151:913–4.
pubmed: 30360292
doi: 10.1016/j.cell.2012.10.025
Yang WL, Wang J, Chan CH, Lee SW, Campos AD, Lamothe B, et al. The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science. 2009;325:1134–8.
pubmed: 19713527
pmcid: 3008763
doi: 10.1126/science.1175065
Feng H, Lopez GY, Kim CK, Alvarez A, Duncan CG, Nishikawa R, et al. EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. J Clin Investig. 2014;124:3741–56.
pubmed: 25061874
doi: 10.1172/JCI73093
pmcid: 4151226
Warburg O. On the origin of cancer cells. Science. 1956;123:309–14.
pubmed: 13298683
doi: 10.1126/science.123.3191.309
Liu K, Li F, Han H, Chen Y, Mao Z, Luo J, et al. Parkin regulates the activity of pyruvate kinase M2. J Biol Chem. 2016;291:10307–17.
pubmed: 26975375
pmcid: 4858978
doi: 10.1074/jbc.M115.703066
Lee JH, Liu R, Li J, Zhang C, Wang Y, Cai Q, et al. Stabilization of phosphofructokinase 1 platelet isoform by AKT promotes tumorigenesis. Nat Commun. 2017;8:949.
pubmed: 29038421
pmcid: 5643558
doi: 10.1038/s41467-017-00906-9
Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z, et al. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell. 2007;128:129–39.
pubmed: 17218260
pmcid: 1828909
doi: 10.1016/j.cell.2006.11.039
Dai B, Pieper RO, Li D, Wei P, Liu M, Woo SY, et al. FoxM1B regulates NEDD4-1 expression, leading to cellular transformation and full malignant phenotype in immortalized human astrocytes. Cancer Res. 2010;70:2951–61.
pubmed: 20332230
pmcid: 2848915
doi: 10.1158/0008-5472.CAN-09-3909
Hodgson JG, Yeh RF, Ray A, Wang NJ, Smirnov I, Yu M, et al. Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. Neuro Oncol. 2009;11:477–87.
pubmed: 19139420
pmcid: 2765338
doi: 10.1215/15228517-2008-113
Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol. 1999;9:661–4.
pubmed: 10375532
doi: 10.1016/S0960-9822(99)80290-5
Mamillapalli R, Gavrilova N, Mihaylova VT, Tsvetkov LM, Wu H, Zhang H, et al. PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27(KIP1) through the ubiquitin E3 ligase SCF(SKP2). Curr Biol. 2001;11:263–7.
pubmed: 11250155
doi: 10.1016/S0960-9822(01)00065-3
Piotrowski A, Xie J, Liu YF, Poplawski AB, Gomes AR, Madanecki P, et al. Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas. Nat Genet. 2014;46:182–7.
pubmed: 24362817
doi: 10.1038/ng.2855
Yamamoto GL, Aguena M, Gos M, Hung C, Pilch J, Fahiminiya S, et al. Rare variants in SOS2 and LZTR1 are associated with Noonan syndrome. J Med Genet. 2015;52:413–21.
pubmed: 25795793
doi: 10.1136/jmedgenet-2015-103018
Frattini V, Trifonov V, Chan JM, Castano A, Lia M, Abate F, et al. The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet. 2013;45:1141–9.
pubmed: 23917401
pmcid: 3799953
doi: 10.1038/ng.2734
Steklov M, Pandolfi S, Baietti MF, Batiuk A, Carai P, Najm P, et al. Mutations in LZTR1 drive human disease by dysregulating RAS ubiquitination. Science. 2018;362:1177–82.
pubmed: 30442762
doi: 10.1126/science.aap7607
pmcid: 8058620
Bigenzahn JW, Collu GM, Kartnig F, Pieraks M, Vladimer GI, Heinz LX, et al. LZTR1 is a regulator of RAS ubiquitination and signaling. Science. 2018;362:1171–7.
pubmed: 30442766
pmcid: 6794158
doi: 10.1126/science.aap8210
Abe T, Umeki I, Kanno SI, Inoue SI, Niihori T, Aoki Y. LZTR1 facilitates polyubiquitination and degradation of RAS-GTPases. Cell Death Differ. 2020;27:1023–35.
pubmed: 31337872
doi: 10.1038/s41418-019-0395-5
Gunther HS, Schmidt NO, Phillips HS, Kemming D, Kharbanda S, Soriano R, et al. Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene. 2008;27:2897–909.
pubmed: 18037961
doi: 10.1038/sj.onc.1210949
Fouladkou F, Landry T, Kawabe H, Neeb A, Lu C, Brose N, et al. The ubiquitin ligase Nedd4-1 is dispensable for the regulation of PTEN stability and localization. Proc Natl Acad Sci USA. 2008;105:8585–90.
pubmed: 18562292
doi: 10.1073/pnas.0803233105
pmcid: 2438405
Pao KC, Wood NT, Knebel A, Rafie K, Stanley M, Mabbitt PD, et al. Activity-based E3 ligase profiling uncovers an E3 ligase with esterification activity. Nature. 2018;556:381–5.
pubmed: 29643511
doi: 10.1038/s41586-018-0026-1
Desbois M, Crawley O, Evans PR, Baker ST, Masuho I, Yasuda R, et al. PAM forms an atypical SCF ubiquitin ligase complex that ubiquitinates and degrades NMNAT2. J Biol Chem. 2018;293:13897–909.
pubmed: 29997255
pmcid: 6130950
doi: 10.1074/jbc.RA118.002176
Saiga T, Fukuda T, Matsumoto M, Tada H, Okano HJ, Okano H, et al. Fbxo45 forms a novel ubiquitin ligase complex and is required for neuronal development. Mol Cell Biol. 2009;29:3529–43.
pubmed: 19398581
pmcid: 2698766
doi: 10.1128/MCB.00364-09
Nord H, Hartmann C, Andersson R, Menzel U, Pfeifer S, Piotrowski A, et al. Characterization of novel and complex genomic aberrations in glioblastoma using a 32K BAC array. Neuro Oncol. 2009;11:803–18.
pubmed: 19304958
pmcid: 2802400
doi: 10.1215/15228517-2009-013
Guo Q, Xie J, Dang CV, Liu ET, Bishop JM. Identification of a large Myc-binding protein that contains RCC1-like repeats. Proc Natl Acad Sci USA. 1998;95:9172–7.
pubmed: 9689053
doi: 10.1073/pnas.95.16.9172
pmcid: 21311
Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. Neurofibromatosis type 1. Nat Rev Dis Prim. 2017;3:17004.
pubmed: 28230061
doi: 10.1038/nrdp.2017.4
McGillicuddy LT, Fromm JA, Hollstein PE, Kubek S, Beroukhim R, De Raedt T, et al. Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell. 2009;16:44–54.
pubmed: 19573811
pmcid: 2897249
doi: 10.1016/j.ccr.2009.05.009
Hollstein PE, Cichowski K. Identifying the Ubiquitin Ligase complex that regulates the NF1 tumor suppressor and Ras. Cancer Discov. 2013;3:880–93.
pubmed: 23661552
doi: 10.1158/2159-8290.CD-13-0146
Sato A, Okada M, Shibuya K, Watanabe E, Seino S, Narita Y, et al. Pivotal role for ROS activation of p38 MAPK in the control of differentiation and tumor-initiating capacity of glioma-initiating cells. Stem Cell Res. 2014;12:119–31.
pubmed: 24185179
doi: 10.1016/j.scr.2013.09.012
Zarubin T, Han J. Activation and signaling of the p38 MAP kinase pathway. Cell Res. 2005;15:11–8.
pubmed: 15686620
doi: 10.1038/sj.cr.7290257
Liu J, Han L, Li B, Yang J, Huen MS, Pan X, et al. F-box only protein 31 (FBXO31) negatively regulates p38 mitogen-activated protein kinase (MAPK) signaling by mediating lysine 48-linked ubiquitination and degradation of mitogen-activated protein kinase kinase 6 (MKK6). J Biol Chem. 2014;289:21508–18.
pubmed: 24936062
pmcid: 4118112
doi: 10.1074/jbc.M114.560342
Liu K, Zhang C, Li B, Xie W, Zhang J, Nie X, et al. Mutual stabilization between TRIM9 short isoform and MKK6 potentiates p38 signaling to synergistically suppress glioblastoma progression. Cell Rep. 2018;23:838–51.
pubmed: 29669288
doi: 10.1016/j.celrep.2018.03.096
Yoo YD, Lee DH, Cha-Molstad H, Kim H, Mun SR, Ji C, et al. Glioma-derived cancer stem cells are hypersensitive to proteasomal inhibition. EMBO Rep. 2017;18:150–68.
pubmed: 27993939
doi: 10.15252/embr.201642360
Prager BC, Bhargava S, Mahadev V, Hubert CG, Rich JN. Glioblastoma stem cells: driving resilience through chaos. Trends Cancer 2020;6:223–35.
pubmed: 32101725
doi: 10.1016/j.trecan.2020.01.009
pmcid: 8779821
Suva ML, Tirosh I. The glioma stem cell model in the era of single-cell genomics. Cancer Cell. 2020;37:630–6.
pubmed: 32396858
doi: 10.1016/j.ccell.2020.04.001
Wang H, Wang L, Erdjument-Bromage H, Vidal M, Tempst P, Jones RS, et al. Role of histone H2A ubiquitination in polycomb silencing. Nature. 2004;431:873–8.
pubmed: 15386022
doi: 10.1038/nature02985
Taherbhoy AM, Huang OW, Cochran AG. BMI1-RING1B is an autoinhibited RING E3 ubiquitin ligase. Nat Commun. 2015;6:7621.
pubmed: 26151332
doi: 10.1038/ncomms8621
McGinty RK, Henrici RC, Tan S. Crystal structure of the PRC1 ubiquitylation module bound to the nucleosome. Nature. 2014;514:591–6.
pubmed: 25355358
pmcid: 4215650
doi: 10.1038/nature13890
Bentley ML, Corn JE, Dong KC, Phung Q, Cheung TK, Cochran AG. Recognition of UbcH5c and the nucleosome by the Bmi1/Ring1b ubiquitin ligase complex. EMBO J. 2011;30:3285–97.
pubmed: 21772249
pmcid: 3160663
doi: 10.1038/emboj.2011.243
Moritz LE, Trievel RC. Structure, mechanism, and regulation of polycomb-repressive complex 2. J Biol Chem. 2018;293:13805–14.
pubmed: 28912274
doi: 10.1074/jbc.R117.800367
Jin X, Kim LJY, Wu Q, Wallace LC, Prager BC, Sanvoranart T, et al. Targeting glioma stem cells through combined BMI1 and EZH2 inhibition. Nat Med. 2017;23:1352–61.
pubmed: 29035367
pmcid: 5679732
doi: 10.1038/nm.4415
Chen X, Hu L, Yang H, Ma H, Ye K, Zhao C, et al. DHHC protein family targets different subsets of glioma stem cells in specific niches. J Exp Clin Cancer Res. 2019;38:25.
pubmed: 30658672
pmcid: 6339410
doi: 10.1186/s13046-019-1033-2
Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M. The oncogene and polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature. 1999;397:164–8.
pubmed: 9923679
doi: 10.1038/16476
Haupt Y, Alexander WS, Barri G, Klinken SP, Adams JM. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell. 1991;65:753–63.
pubmed: 1904009
doi: 10.1016/0092-8674(91)90383-A
van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Gulden H, Berns A. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell. 1991;65:737–52.
pubmed: 1904008
doi: 10.1016/0092-8674(91)90382-9
Bruggeman SW, Hulsman D, Tanger E, Buckle T, Blom M, Zevenhoven J, et al. Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell. 2007;12:328–41.
pubmed: 17936558
doi: 10.1016/j.ccr.2007.08.032
Gargiulo G, Cesaroni M, Serresi M, de Vries N, Hulsman D, Bruggeman SW, et al. In vivo RNAi screen for BMI1 targets identifies TGF-beta/BMP-ER stress pathways as key regulators of neural- and malignant glioma-stem cell homeostasis. Cancer Cell. 2013;23:660–76.
pubmed: 23680149
doi: 10.1016/j.ccr.2013.03.030
Abdouh M, Facchino S, Chatoo W, Balasingam V, Ferreira J, Bernier G. BMI1 sustains human glioblastoma multiforme stem cell renewal. J Neurosci. 2009;29:8884–96.
pubmed: 19605626
pmcid: 6665439
doi: 10.1523/JNEUROSCI.0968-09.2009
Godlewski J, Nowicki MO, Bronisz A, Williams S, Otsuki A, Nuovo G, et al. Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res. 2008;68:9125–30.
pubmed: 19010882
doi: 10.1158/0008-5472.CAN-08-2629
Facchino S, Abdouh M, Chatoo W, Bernier G. BMI1 confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery. J Neurosci. 2010;30:10096–111.
pubmed: 20668194
pmcid: 6633363
doi: 10.1523/JNEUROSCI.1634-10.2010
Lee Y, Lee JK, Ahn SH, Lee J, Nam DH. WNT signaling in glioblastoma and therapeutic opportunities. Lab Investig. 2016;96:137–50.
pubmed: 26641068
doi: 10.1038/labinvest.2015.140
Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol. 2007;17:165–72.
pubmed: 17196391
doi: 10.1016/j.cub.2006.11.033
Jin X, Jeon HM, Jin X, Kim EJ, Yin J, Jeon HY, et al. The ID1-CULLIN3 axis regulates intracellular SHH and WNT signaling in glioblastoma stem cells. Cell Rep. 2016;16:1629–41.
pubmed: 27477274
doi: 10.1016/j.celrep.2016.06.092
Wald JH, Hatakeyama J, Printsev I, Cuevas A, Fry WHD, Saldana MJ, et al. Suppression of planar cell polarity signaling and migration in glioblastoma by Nrdp1-mediated Dvl polyubiquitination. Oncogene. 2017;36:5158–67.
pubmed: 28481871
pmcid: 5589482
doi: 10.1038/onc.2017.126
Ooi L, Wood IC. Chromatin crosstalk in development and disease: lessons from REST. Nat Rev Genet. 2007;8:544–54.
pubmed: 17572692
doi: 10.1038/nrg2100
Kamal MM, Sathyan P, Singh SK, Zinn PO, Marisetty AL, Liang S, et al. REST regulates oncogenic properties of glioblastoma stem cells. Stem Cells. 2012;30:405–14.
pubmed: 22228704
pmcid: 4039365
doi: 10.1002/stem.1020
Marisetty AL, Lu L, Veo BL, Liu B, Coarfa C, Kamal MM, et al. REST-DRD2 mechanism impacts glioblastoma stem cell-mediated tumorigenesis. Neuro Oncol. 2019;21:775–85.
pubmed: 30953587
pmcid: 6556851
doi: 10.1093/neuonc/noz030
Zhang P, Lathia JD, Flavahan WA, Rich JN, Mattson MP. Squelching glioblastoma stem cells by targeting REST for proteasomal degradation. Trends Neurosci. 2009;32:559–65.
pubmed: 19748686
pmcid: 2767465
doi: 10.1016/j.tins.2009.07.005
Guardavaccaro D, Frescas D, Dorrello NV, Peschiaroli A, Multani AS, Cardozo T, et al. Control of chromosome stability by the beta-TrCP-REST-Mad2 axis. Nature. 2008;452:365–9.
pubmed: 18354482
pmcid: 2707768
doi: 10.1038/nature06641
Westbrook TF, Hu G, Ang XL, Mulligan P, Pavlova NN, Liang A, et al. SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation. Nature. 2008;452:370–4.
pubmed: 18354483
pmcid: 2688689
doi: 10.1038/nature06780
Fang X, Zhou W, Wu Q, Huang Z, Shi Y, Yang K, et al. Deubiquitinase USP13 maintains glioblastoma stem cells by antagonizing FBXL14-mediated Myc ubiquitination. J Exp Med. 2017;214:245–67.
pubmed: 27923907
pmcid: 5206492
doi: 10.1084/jem.20151673
Chen F, Zhang C, Wu H, Ma Y, Luo X, Gong X, et al. The E3 ubiquitin ligase SCF(FBXL14) complex stimulates neuronal differentiation by targeting the Notch signaling factor HES1 for proteolysis. J Biol Chem. 2017;292:20100–12.
pubmed: 29070679
pmcid: 5723999
doi: 10.1074/jbc.M117.815001
Zhao X, D DA, Lim WK, Brahmachary M, Carro MS, Ludwig T, et al. The N-Myc-DLL3 cascade is suppressed by the ubiquitin ligase Huwe1 to inhibit proliferation and promote neurogenesis in the developing brain. Dev Cell. 2009;17:210–21.
pubmed: 19686682
pmcid: 2769073
doi: 10.1016/j.devcel.2009.07.009
Vincent SR, Kwasnicka DA, Fretier P. A novel RING finger-B box-coiled-coil protein, GERP. Biochem Biophys Res Commun. 2000;279:482–6.
pubmed: 11118312
doi: 10.1006/bbrc.2000.3984
Zhang C, Mukherjee S, Tucker-Burden C, Ross JL, Chau MJ, Kong J, et al. TRIM8 regulates stemness in glioblastoma through PIAS3-STAT3. Mol Oncol. 2017;11:280–94.
pubmed: 28100038
pmcid: 5332279
doi: 10.1002/1878-0261.12034
Venuto S, Castellana S, Monti M, Appolloni I, Fusilli C, Fusco C, et al. TRIM8-driven transcriptomic profile of neural stem cells identified glioma-related nodal genes and pathways. Biochim Biophys Acta Gen Subj. 2019;1863:491–501.
pubmed: 30528352
doi: 10.1016/j.bbagen.2018.12.001
Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98–110.
pubmed: 20129251
pmcid: 2818769
doi: 10.1016/j.ccr.2009.12.020
Mao DD, Gujar AD, Mahlokozera T, Chen I, Pan Y, Luo J, et al. A CDC20-APC/SOX2 signaling axis regulates human glioblastoma stem-like cells. Cell Rep. 2015;11:1809–21.
pubmed: 26074073
pmcid: 4481182
doi: 10.1016/j.celrep.2015.05.027
Cui CP, Zhang Y, Wang C, Yuan F, Li H, Yao Y, et al. Dynamic ubiquitylation of Sox2 regulates proteostasis and governs neural progenitor cell differentiation. Nat Commun. 2018;9:4648.
pubmed: 30405104
pmcid: 6220269
doi: 10.1038/s41467-018-07025-z
Tang M, Xie Q, Gimple RC, Zhong Z, Tam T, Tian J, et al. Three-dimensional bioprinted glioblastoma microenvironments model cellular dependencies and immune interactions. Cell Res. 2020;30:833–53.
Fernald K, Kurokawa M. Evading apoptosis in cancer. Trends Cell Biol. 2013;23:620–33.
pubmed: 23958396
pmcid: 4091735
doi: 10.1016/j.tcb.2013.07.006
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–74.
pubmed: 21376230
doi: 10.1016/j.cell.2011.02.013
Fulda S. Cell death-based treatment of glioblastoma. Cell Death Dis. 2018;9:121.
pubmed: 29371590
pmcid: 5833770
doi: 10.1038/s41419-017-0021-8
Hsu H, Shu HB, Pan MG, Goeddel DV. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell. 1996;84:299–308.
pubmed: 8565075
doi: 10.1016/S0092-8674(00)80984-8
Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell. 1995;81:495–504.
pubmed: 7758105
doi: 10.1016/0092-8674(95)90070-5
Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 2003;114:181–90.
pubmed: 12887920
doi: 10.1016/S0092-8674(03)00521-X
Darding M, Meier P. IAPs: guardians of RIPK1. Cell Death Differ. 2012;19:58–66.
pubmed: 22095281
doi: 10.1038/cdd.2011.163
Rothe M, Pan MG, Henzel WJ, Ayres TM, Goeddel DV. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell. 1995;83:1243–52.
pubmed: 8548810
doi: 10.1016/0092-8674(95)90149-3
Witt A, Vucic D. Diverse ubiquitin linkages regulate RIP kinases-mediated inflammatory and cell death signaling. Cell Death Differ. 2017;24:1160–71.
pubmed: 28475174
pmcid: 5520166
doi: 10.1038/cdd.2017.33
Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J, et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell. 2008;30:689–700.
doi: 10.1016/j.molcel.2008.05.014
pubmed: 18570872
Dynek JN, Goncharov T, Dueber EC, Fedorova AV, Izrael-Tomasevic A, Phu L, et al. c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling. EMBO J. 2010;29:4198–209.
pubmed: 21113135
pmcid: 3018797
doi: 10.1038/emboj.2010.300
Park SM, Yoon JB, Lee TH. Receptor interacting protein is ubiquitinated by cellular inhibitor of apoptosis proteins (c-IAP1 and c-IAP2) in vitro. FEBS Lett. 2004;566:151–6.
pubmed: 15147886
doi: 10.1016/j.febslet.2004.04.021
Haas TL, Emmerich CH, Gerlach B, Schmukle AC, Cordier SM, Rieser E, et al. Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol Cell. 2009;36:831–44.
pubmed: 20005846
doi: 10.1016/j.molcel.2009.10.013
Taniguchi K, Karin MNF-kappaB. inflammation, immunity and cancer: coming of age. Nat Rev Immunol. 2018;18:309–24.
pubmed: 29379212
doi: 10.1038/nri.2017.142
Park S, Hatanpaa KJ, Xie Y, Mickey BE, Madden CJ, Raisanen JM, et al. The receptor interacting protein 1 inhibits p53 induction through NF-kappaB activation and confers a worse prognosis in glioblastoma. Cancer Res. 2009;69:2809–16.
pubmed: 19339267
pmcid: 2859885
doi: 10.1158/0008-5472.CAN-08-4079
Chen X, Tai L, Gao J, Qian J, Zhang M, Li B, et al. A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation. J Control Release. 2015;218:29–35.
pubmed: 26428461
pmcid: 5878090
doi: 10.1016/j.jconrel.2015.09.061
Her NG, Oh JW, Oh YJ, Han S, Cho HJ, Lee Y, et al. Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells. Cell Death Dis. 2018;9:792.
pubmed: 30022047
pmcid: 6052082
doi: 10.1038/s41419-018-0825-1
Kim M, Ma DJ, Calligaris D, Zhang S, Feathers RW, Vaubel RA, et al. Efficacy of the MDM2 inhibitor SAR405838 in glioblastoma is limited by poor distribution across the blood-brain barrier. Mol Cancer Ther. 2018;17:1893–901.
pubmed: 29970480
pmcid: 6125211
doi: 10.1158/1535-7163.MCT-17-0600
Zhang Y, Dube C, Gibert M, Jr, Cruickshanks N, Wang B, Coughlan M, et al. The p53 Pathway in Glioblastoma. Cancers (Basel). 2018;10:297.
Berger R, Jennewein C, Marschall V, Karl S, Cristofanon S, Wagner L, et al. NF-kappaB is required for Smac mimetic-mediated sensitization of glioblastoma cells for gamma-irradiation-induced apoptosis. Mol Cancer Ther. 2011;10:1867–75.
pubmed: 21859841
doi: 10.1158/1535-7163.MCT-11-0218
Zheng M, Morgan-Lappe SE, Yang J, Bockbrader KM, Pamarthy D, Thomas D, et al. Growth inhibition and radiosensitization of glioblastoma and lung cancer cells by small interfering RNA silencing of tumor necrosis factor receptor-associated factor 2. Cancer Res. 2008;68:7570–8.
pubmed: 18794145
pmcid: 2597026
doi: 10.1158/0008-5472.CAN-08-0632
Vellanki SH, Grabrucker A, Liebau S, Proepper C, Eramo A, Braun V, et al. Small-molecule XIAP inhibitors enhance gamma-irradiation-induced apoptosis in glioblastoma. Neoplasia. 2009;11:743–52.
pubmed: 19649204
pmcid: 2713593
doi: 10.1593/neo.09436
Wagner L, Marschall V, Karl S, Cristofanon S, Zobel K, Deshayes K, et al. Smac mimetic sensitizes glioblastoma cells to temozolomide-induced apoptosis in a RIP1- and NF-kappaB-dependent manner. Oncogene. 2013;32:988–97.
pubmed: 22469979
doi: 10.1038/onc.2012.108
Zakaria Z, Tivnan A, Flanagan L, Murray DW, Salvucci M, Stringer BW, et al. Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant. Br J Cancer. 2016;114:188–98.
pubmed: 26657652
doi: 10.1038/bjc.2015.420
Beug ST, Beauregard CE, Healy C, Sanda T, St-Jean M, Chabot J, et al. Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma. Nat Commun. 2017;8:14278.
Tenev T, Bianchi K, Darding M, Broemer M, Langlais C, Wallberg F, et al. The ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell. 2011;43:432–48.
pubmed: 21737329
doi: 10.1016/j.molcel.2011.06.006
Puliyappadamba VT, Chakraborty S, Chauncey SS, Li L, Hatanpaa KJ, Mickey B, et al. Opposing effect of EGFRWT on EGFRvIII-mediated NF-kappaB activation with RIP1 as a cell death switch. Cell Rep. 2013;4:764–75.
pubmed: 23972990
pmcid: 3780989
doi: 10.1016/j.celrep.2013.07.025
Shembade N, Harhaj EW. Regulation of NF-kappaB signaling by the A20 deubiquitinase. Cell Mol Immunol. 2012;9:123–30.
pubmed: 22343828
pmcid: 3532050
doi: 10.1038/cmi.2011.59
Bredel M, Bredel C, Juric D, Duran GE, Yu RX, Harsh GR, et al. Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. J Clin Oncol. 2006;24:274–87.
pubmed: 16365179
doi: 10.1200/JCO.2005.02.9405
Haemmig S, Baumgartner U, Gluck A, Zbinden S, Tschan MP, Kappeler A, et al. miR-125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas. Cell Death Dis. 2014;5:e1279.
pubmed: 24901050
pmcid: 4611719
doi: 10.1038/cddis.2014.245
Hjelmeland AB, Wu Q, Wickman S, Eyler C, Heddleston J, Shi Q, et al. Targeting A20 decreases glioma stem cell survival and tumor growth. PLoS Biol. 2010;8:e1000319.
pubmed: 20186265
pmcid: 2826371
doi: 10.1371/journal.pbio.1000319
von Karstedt S, Montinaro A, Walczak H. Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. Nat Rev Cancer. 2017;17:352–66.
doi: 10.1038/nrc.2017.28
Bellail AC, Olson JJ, Yang X, Chen ZJ, Hao C. A20 ubiquitin ligase-mediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma. Cancer Discov. 2012;2:140–55.
pubmed: 22585859
pmcid: 3354650
doi: 10.1158/2159-8290.CD-11-0172
Panner A, Crane CA, Weng C, Feletti A, Fang S, Parsa AT, et al. Ubiquitin-specific protease 8 links the PTEN-Akt-AIP4 pathway to the control of FLIPS stability and TRAIL sensitivity in glioblastoma multiforme. Cancer Res. 2010;70:5046–53.
pubmed: 20484045
pmcid: 2891229
doi: 10.1158/0008-5472.CAN-09-3979
Panner A, Crane CA, Weng C, Feletti A, Parsa AT, Pieper RO. A novel PTEN-dependent link to ubiquitination controls FLIPS stability and TRAIL sensitivity in glioblastoma multiforme. Cancer Res. 2009;69:7911–6.
pubmed: 19808964
pmcid: 3229302
doi: 10.1158/0008-5472.CAN-09-1287
Jin Z, Li Y, Pitti R, Lawrence D, Pham VC, Lill JR, et al. Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell. 2009;137:721–35.
pubmed: 19427028
doi: 10.1016/j.cell.2009.03.015
Humphreys LM, Fox JP, Higgins CA, Majkut J, Sessler T, McLaughlin K, et al. A revised model of TRAIL-R2 DISC assembly explains how FLIP(L) can inhibit or promote apoptosis. EMBO Rep. 2020;21:e49254.
pubmed: 32009295
pmcid: 7054686
doi: 10.15252/embr.201949254
Roberts JZ, Holohan C, Sessler T, Fox J, Crawford N, Riley JS, et al. The SCF(Skp2) ubiquitin ligase complex modulates TRAIL-R2-induced apoptosis by regulating FLIP(L). Cell Death Differ. 2020;27:2726–41.
Zhang H, Chen ZH, Savarese TM. Codeletion of the genes for p16INK4, methylthioadenosine phosphorylase, interferon-alpha1, interferon-beta1, and other 9p21 markers in human malignant cell lines. Cancer Genet Cytogenet. 1996;86:22–8.
pubmed: 8616780
doi: 10.1016/0165-4608(95)00157-3
Albers E. Metabolic characteristics and importance of the universal methionine salvage pathway recycling methionine from 5’-methylthioadenosine. IUBMB Life. 2009;61:1132–42.
pubmed: 19946895
doi: 10.1002/iub.278
Kryukov GV, Wilson FH, Ruth JR, Paulk J, Tsherniak A, Marlow SE, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351:1214–8.
pubmed: 26912360
pmcid: 4997612
doi: 10.1126/science.aad5214
Doil C, Mailand N, Bekker-Jensen S, Menard P, Larsen DH, Pepperkok R, et al. RNF168 binds and amplifies ubiquitin conjugates on damaged chromosomes to allow accumulation of repair proteins. Cell. 2009;136:435–46.
pubmed: 19203579
doi: 10.1016/j.cell.2008.12.041
Bohgaki M, Bohgaki T, El Ghamrasni S, Srikumar T, Maire G, Panier S, et al. RNF168 ubiquitylates 53BP1 and controls its response to DNA double-strand breaks. Proc Natl Acad Sci USA. 2013;110:20982–7.
pubmed: 24324146
doi: 10.1073/pnas.1320302111
pmcid: 3876264
Du C, Hansen LJ, Singh SX, Wang F, Sun R, Moure CJ, et al. A PRMT5-RNF168-SMURF2 axis controls H2AX proteostasis. Cell Rep. 2019;28:3199–211e5.
pubmed: 31533041
pmcid: 7204040
doi: 10.1016/j.celrep.2019.08.031
Wang Y, Hou Y, Zhang W, Alvarez AA, Bai Y, Hu B, et al. Lipolytic inhibitor G0S2 modulates glioma stem-like cell radiation response. J Exp Clin Cancer Res. 2019;38:147.
pubmed: 30953555
pmcid: 6451284
doi: 10.1186/s13046-019-1151-x
Lee K, Byun K, Hong W, Chuang HY, Pack CG, Bayarsaikhan E, et al. Proteome-wide discovery of mislocated proteins in cancer. Genome Res. 2013;23:1283–94.
pubmed: 23674306
pmcid: 3730102
doi: 10.1101/gr.155499.113
Kim W, Youn H, Lee S, Kim E, Kim D, Sub Lee J, et al. RNF138-mediated ubiquitination of rpS3 is required for resistance of glioblastoma cells to radiation-induced apoptosis. Exp Mol Med. 2018;50:e434.
pubmed: 29371697
pmcid: 5799804
doi: 10.1038/emm.2017.247
Liang J, Cao R, Wang X, Zhang Y, Wang P, Gao H, et al. Mitochondrial PKM2 regulates oxidative stress-induced apoptosis by stabilizing Bcl2. Cell Res. 2017;27:329–51.
pubmed: 28035139
doi: 10.1038/cr.2016.159
Ashkenazi A, Fairbrother WJ, Leverson JD, Souers AJ. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat Rev Drug Discov. 2017;16:273–84.
pubmed: 28209992
doi: 10.1038/nrd.2016.253
Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141:1117–34.
pubmed: 20602996
pmcid: 2914105
doi: 10.1016/j.cell.2010.06.011
Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res. 2006;12:5268–72.
pubmed: 17000658
doi: 10.1158/1078-0432.CCR-05-1554
Hoxhaj G, Manning BD. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 2020;20:74–88.
pubmed: 31686003
doi: 10.1038/s41568-019-0216-7
Brognard J, Sierecki E, Gao T, Newton AC. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell. 2007;25:917–31.
pubmed: 17386267
doi: 10.1016/j.molcel.2007.02.017
Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26:3279–90.
pubmed: 17496922
doi: 10.1038/sj.onc.1210421
Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011;11:761–74.
pubmed: 21993244
pmcid: 3632399
doi: 10.1038/nrc3106
Bunda S, Heir P, Metcalf J, Li ASC, Agnihotri S, Pusch S, et al. CIC protein instability contributes to tumorigenesis in glioblastoma. Nat Commun. 2019;10:661.
pubmed: 30737375
pmcid: 6368580
doi: 10.1038/s41467-018-08087-9
Priem D, van Loo G, Bertrand MJM. A20 and cell death-driven inflammation. Trends Immunol. 2020;41:421–35.
pubmed: 32241683
doi: 10.1016/j.it.2020.03.001
Kaur E, Rajendra J, Jadhav S, Shridhar E, Goda JS, Moiyadi A, et al. Radiation-induced homotypic cell fusions of innately resistant glioblastoma cells mediate their sustained survival and recurrence. Carcinogenesis. 2015;36:685–95.
pubmed: 25863126
doi: 10.1093/carcin/bgv050
Wang D, Berglund A, Kenchappa RS, Forsyth PA, Mule JJ, Etame AB. BIRC3 is a novel driver of therapeutic resistance in Glioblastoma. Sci Rep. 2016;6:21710.
pubmed: 26888114
pmcid: 4757860
doi: 10.1038/srep21710
Bertrand MJ, Lippens S, Staes A, Gilbert B, Roelandt R, De Medts J, et al. cIAP1/2 are direct E3 ligases conjugating diverse types of ubiquitin chains to receptor interacting proteins kinases 1 to 4 (RIP1-4). PLoS ONE. 2011;6:e22356.
pubmed: 21931591
pmcid: 3171409
doi: 10.1371/journal.pone.0022356
Galban S, Duckett CS. XIAP as a ubiquitin ligase in cellular signaling. Cell Death Differ. 2010;17:54–60.
pubmed: 19590513
doi: 10.1038/cdd.2009.81
Suzuki Y, Nakabayashi Y, Takahashi R. Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc Natl Acad Sci USA. 2001;98:8662–7.
pubmed: 11447297
doi: 10.1073/pnas.161506698
pmcid: 37492
Riedl SJ, Renatus M, Schwarzenbacher R, Zhou Q, Sun C, Fesik SW, et al. Structural basis for the inhibition of caspase-3 by XIAP. Cell. 2001;104:791–800.
pubmed: 11257232
doi: 10.1016/S0092-8674(01)00274-4
Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell. 2000;102:43–53.
pubmed: 10929712
doi: 10.1016/S0092-8674(00)00009-X
Arora V, Cheung HH, Plenchette S, Micali OC, Liston P, Korneluk RG. Degradation of survivin by the X-linked inhibitor of apoptosis (XIAP)-XAF1 complex. J Biol Chem. 2007;282:26202–9.
pubmed: 17613533
doi: 10.1074/jbc.M700776200